The PPARγ agonist rosiglitazone suppresses syngeneic mouse SCC (squamous cell carcinoma) tumor growth through an immune-mediated mechanism

Raymond Konger, Ethel Derr-Yellin, Nurmukambed Ermatov, Lu Ren, Ravi P. Sahu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Recent evidence suggests that PPARγ agonists may promote anti-tumor immunity. We show that immunogenic PDV cutaneous squamous cell carcinoma (CSCC) tumors are rejected when injected intradermally at a low cell number (1 × 106) into immune competent syngeneic hosts, but not immune deficient mice. At higher cell numbers (5 × 106 PDV cells), progressively growing tumors were established in 14 of 15 vehicle treated mice while treatment of mice with the PPARγ agonist rosiglitazone resulted in increased tumor rejection (5 of 14 tumors), a significant decrease in PDV tumor size, and a significant decrease in tumor cell Ki67 labeling. Rosiglitazone treatment had no effect on tumor rejection, tumor volume or PDV tumor cell proliferation in immune deficient NOD.CB17-PrkdcSCID/J mice. Rosiglitazone treatment also promoted an increase in tumor infiltrating CD3+ T-cells at both early and late time points. In contrast, rosiglitazone treatment had no significant effect on myeloid cells expressing either CD11b or Gr-1 but suppressed a late accumulation of myeloid cells expressing both CD11b and Gr-1, suggesting a potential role for CD11b+Gr-1+ myeloid cells in the late anti-tumor immune response. Overall, our data provides evidence that the PPARγ agonist rosiglitazone promotes immune-mediated anti-neoplastic activity against tumors derived from this immunogenic CSCC cell line.

Original languageEnglish (US)
Article number2192
JournalMolecules
Volume24
Issue number11
DOIs
StatePublished - Jun 11 2019

Fingerprint

rosiglitazone
Peroxisome Proliferator-Activated Receptors
mice
Tumors
Squamous Cell Carcinoma
tumors
cancer
Growth
Neoplasms
Myeloid Cells
Cells
cells
rejection
Epithelial Cells
Cell Count

Keywords

  • Anti-tumor immunity
  • Myeloid cells
  • Peroxisome proliferator activated receptor gamma
  • Rosiglitazone
  • T-cells

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Cite this

The PPARγ agonist rosiglitazone suppresses syngeneic mouse SCC (squamous cell carcinoma) tumor growth through an immune-mediated mechanism. / Konger, Raymond; Derr-Yellin, Ethel; Ermatov, Nurmukambed; Ren, Lu; Sahu, Ravi P.

In: Molecules, Vol. 24, No. 11, 2192, 11.06.2019.

Research output: Contribution to journalArticle

@article{2de6e0ce2d1749beae00ef80c0883d53,
title = "The PPARγ agonist rosiglitazone suppresses syngeneic mouse SCC (squamous cell carcinoma) tumor growth through an immune-mediated mechanism",
abstract = "Recent evidence suggests that PPARγ agonists may promote anti-tumor immunity. We show that immunogenic PDV cutaneous squamous cell carcinoma (CSCC) tumors are rejected when injected intradermally at a low cell number (1 × 106) into immune competent syngeneic hosts, but not immune deficient mice. At higher cell numbers (5 × 106 PDV cells), progressively growing tumors were established in 14 of 15 vehicle treated mice while treatment of mice with the PPARγ agonist rosiglitazone resulted in increased tumor rejection (5 of 14 tumors), a significant decrease in PDV tumor size, and a significant decrease in tumor cell Ki67 labeling. Rosiglitazone treatment had no effect on tumor rejection, tumor volume or PDV tumor cell proliferation in immune deficient NOD.CB17-PrkdcSCID/J mice. Rosiglitazone treatment also promoted an increase in tumor infiltrating CD3+ T-cells at both early and late time points. In contrast, rosiglitazone treatment had no significant effect on myeloid cells expressing either CD11b or Gr-1 but suppressed a late accumulation of myeloid cells expressing both CD11b and Gr-1, suggesting a potential role for CD11b+Gr-1+ myeloid cells in the late anti-tumor immune response. Overall, our data provides evidence that the PPARγ agonist rosiglitazone promotes immune-mediated anti-neoplastic activity against tumors derived from this immunogenic CSCC cell line.",
keywords = "Anti-tumor immunity, Myeloid cells, Peroxisome proliferator activated receptor gamma, Rosiglitazone, T-cells",
author = "Raymond Konger and Ethel Derr-Yellin and Nurmukambed Ermatov and Lu Ren and Sahu, {Ravi P.}",
year = "2019",
month = "6",
day = "11",
doi = "10.3390/molecules24112192",
language = "English (US)",
volume = "24",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - The PPARγ agonist rosiglitazone suppresses syngeneic mouse SCC (squamous cell carcinoma) tumor growth through an immune-mediated mechanism

AU - Konger, Raymond

AU - Derr-Yellin, Ethel

AU - Ermatov, Nurmukambed

AU - Ren, Lu

AU - Sahu, Ravi P.

PY - 2019/6/11

Y1 - 2019/6/11

N2 - Recent evidence suggests that PPARγ agonists may promote anti-tumor immunity. We show that immunogenic PDV cutaneous squamous cell carcinoma (CSCC) tumors are rejected when injected intradermally at a low cell number (1 × 106) into immune competent syngeneic hosts, but not immune deficient mice. At higher cell numbers (5 × 106 PDV cells), progressively growing tumors were established in 14 of 15 vehicle treated mice while treatment of mice with the PPARγ agonist rosiglitazone resulted in increased tumor rejection (5 of 14 tumors), a significant decrease in PDV tumor size, and a significant decrease in tumor cell Ki67 labeling. Rosiglitazone treatment had no effect on tumor rejection, tumor volume or PDV tumor cell proliferation in immune deficient NOD.CB17-PrkdcSCID/J mice. Rosiglitazone treatment also promoted an increase in tumor infiltrating CD3+ T-cells at both early and late time points. In contrast, rosiglitazone treatment had no significant effect on myeloid cells expressing either CD11b or Gr-1 but suppressed a late accumulation of myeloid cells expressing both CD11b and Gr-1, suggesting a potential role for CD11b+Gr-1+ myeloid cells in the late anti-tumor immune response. Overall, our data provides evidence that the PPARγ agonist rosiglitazone promotes immune-mediated anti-neoplastic activity against tumors derived from this immunogenic CSCC cell line.

AB - Recent evidence suggests that PPARγ agonists may promote anti-tumor immunity. We show that immunogenic PDV cutaneous squamous cell carcinoma (CSCC) tumors are rejected when injected intradermally at a low cell number (1 × 106) into immune competent syngeneic hosts, but not immune deficient mice. At higher cell numbers (5 × 106 PDV cells), progressively growing tumors were established in 14 of 15 vehicle treated mice while treatment of mice with the PPARγ agonist rosiglitazone resulted in increased tumor rejection (5 of 14 tumors), a significant decrease in PDV tumor size, and a significant decrease in tumor cell Ki67 labeling. Rosiglitazone treatment had no effect on tumor rejection, tumor volume or PDV tumor cell proliferation in immune deficient NOD.CB17-PrkdcSCID/J mice. Rosiglitazone treatment also promoted an increase in tumor infiltrating CD3+ T-cells at both early and late time points. In contrast, rosiglitazone treatment had no significant effect on myeloid cells expressing either CD11b or Gr-1 but suppressed a late accumulation of myeloid cells expressing both CD11b and Gr-1, suggesting a potential role for CD11b+Gr-1+ myeloid cells in the late anti-tumor immune response. Overall, our data provides evidence that the PPARγ agonist rosiglitazone promotes immune-mediated anti-neoplastic activity against tumors derived from this immunogenic CSCC cell line.

KW - Anti-tumor immunity

KW - Myeloid cells

KW - Peroxisome proliferator activated receptor gamma

KW - Rosiglitazone

KW - T-cells

UR - http://www.scopus.com/inward/record.url?scp=85067235921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067235921&partnerID=8YFLogxK

U2 - 10.3390/molecules24112192

DO - 10.3390/molecules24112192

M3 - Article

C2 - 31212694

AN - SCOPUS:85067235921

VL - 24

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 11

M1 - 2192

ER -